Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
68.42 USD | -0.34% | -1.77% | +56.93% |
04-11 | Berenberg Reiterates UCB's Purchase Rating, Raises PT | MT |
04-11 | UCB : Berenberg, Buy, raises its price target | CF |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The company's profit outlook over the next few years is a strong asset.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- With an expected P/E ratio at 60.47 and 27.99 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's enterprise value to sales, at 4.56 times its current sales, is high.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last few months, analysts have been revising downwards their earnings forecast.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+56.93% | 26.03B | - | ||
-2.29% | 89.38B | A- | ||
-3.68% | 37.92B | A- | ||
-14.91% | 32.04B | B- | ||
-22.72% | 14.14B | C | ||
-8.73% | 12.88B | B- | ||
-10.57% | 11.77B | D+ | ||
+4.34% | 8.92B | B+ | ||
-17.66% | 7.34B | B- | ||
+82.74% | 6.96B | D |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- UCB Stock
- UCBJY Stock
- Ratings UCB SA